title: [Rhabdomyolysis from gabapentin: a case report].
abstract: Gabapentin (GBP) is a drug with different indications.Is not metabolized and is excreted by the kidney. The common side effects are: arthralgia, myalgia, fatigue, dizziness and ataxia. Rhabdomyolysis is an extremely rare side effect. This latter, that can be caused by trauma, strenuous exercise, infections, drugs and toxins, is a syndrome characterized by loss of skeletal muscle resulting in the release of myocyte components in the circulation. Following a case of rhabdomyolysis caused by GBP in patient with chronic renal failure (CRF). A 65-year-old diabetic men, in peritoneal dialysis (PD), affected by ischemic and hypokinetic cardiomyopathy, sensorimotor neuropathy. The patient reported: weakness, diffuse myalgias, hypotension. He had been taking GBP for three days, after the failure of therapies with tricyclic antidepressants, opioids and NSAIDs. Laboratory tests confirmed the increase of the indices of muscle necrosis.The immediate withdrawal of the drug in association with CAPD dialysis treatment, led to improvement of the clinical and biochemical parameters. During the last 10 years, 3 cases of rhabdomyolysis referred to the assumption of GBP have been reported. The use of PD for treatment of acute renal failure, has been significantly reduced over the years. The effectiveness of the purification method is much lower than the one with the continuous extracorporeal treatments. In conclusion, GBP may be associated with rhabdomyolysis. Since GBP toxicity in CRF patients is often overlooked, a better awareness of this phenomenon and a thorough follow-up of laboratory tests to detect any possible early adverse reaction is suggested.
authors.forename: Daniela
authors.initials: D
authors.lastname: Falconi
authors.forename: Fabio
authors.initials: F
authors.lastname: Tattoli
authors.forename: Carlo
authors.initials: C
authors.lastname: Brunetti
authors.forename: Ornella
authors.initials: O
authors.lastname: De Prisco
authors.forename: Maurizio
authors.initials: M
authors.lastname: Gherzi
authors.forename: Federico
authors.initials: F
authors.lastname: Marazzi
authors.forename: Marita
authors.initials: M
authors.lastname: Marengo
authors.forename: Ilaria
authors.initials: I
authors.lastname: Serra
authors.forename: Michela
authors.initials: M
authors.lastname: Tamagnone
authors.forename: Marco
authors.initials: M
authors.lastname: Formica
mesh_terms: D000368:Aged; D000588:Amines / Q000009:adverse effects*; D000700:Analgesics / Q000009:adverse effects*; D003509:Cyclohexanecarboxylic Acids / Q000009:adverse effects*; D000077206:Gabapentin; D006801:Humans; D008297:Male; D010530:Peritoneal Dialysis; D012206:Rhabdomyolysis / Q000139:chemically induced*; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects*
chemical_list: D000588:Amines; D000700:Analgesics; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin